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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent malignancy owing to intrinsic
radioresistance and lack of induction of apoptosis. The major focus of this work was to design a transient glutathione
depleting strategy during the course of irradiation of HNSCC in order to overcome their radioresistance associated with
redox adaptation.
Methodology/Principal Findings: Treatment of SQ20B cells with dimethylfumarate (DMF), a GSH-depleting agent, and L-
Buthionine sulfoximine (BSO), an inhibitor of GSH biosynthesis 4 h before a 10 Gy irradiation led to the lowering of the
endogenous GSH content to less than 10% of that in control cells and to the triggering of radiation-induced apoptotic cell
death. The sequence of biochemical events after GSH depletion and irradiation included ASK-1 followed by JNK activation
which resulted in the triggering of the intrinsic apoptotic pathway through Bax translocation to mitochondria.
Conclusions: This transient GSH depletion also triggered radiation-induced cell death in SQ20B stem cells, a key event to
overcome locoregional recurrence of HNSCC. Finally, our in vivo data highlight the relevance for further clinical trials of
endogenous redox modulation to enhance the cytotoxic effects of radiotherapy.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is among
the 10 most common cancers worldwide [1] and, despite new basic
and clinical information, the overall 5-year survival rate for
HNSCC remains as low as 50% [2]. Along with surgery,
radiotherapy plays a key role in the management of early stage
and locally advanced HNSCC either alone or, more frequently
combined with surgery and/or chemotherapy. In the past few
years, a significant 5-year local control and overall survival benefit
has been the introduction of concomitant chemoradiotherapy or
molecular targeted therapy combined with irradiation [3]. The
knowledge about the mechanisms leading to radioresistance and
therefore local recurrence of HNSCC has remained very limited
up to now. We previously demonstrated a lack of induction of
apoptosis in SQ20B cells, a p53 mutated radioresistant HNSCC
cell line following either X-ray [4] or carbon ion irradiation [5].
After a transient arrest in G2/M phase following exposure to X-
rays or more prolonged after carbon ion, some SQ20B cells
undergo mitotic catastrophe whereas the majority of them escape
mitotic catastrophe and re-enter the cell cycle. The development
of adjuvant therapies in order to force the tumour cells to enter
apoptosis after irradiation should therefore be a major improve-
ment towards overcoming the HNSCC resistance to anticancer
treatments [6].
Although many types of cancer cells have increased levels of
reactive oxygen species (ROS), compared with their normal
counterpart [7,8], which may play an important role in the
initiation and progression of cancer [9,10], excessive levels of ROS
can also be toxic to these cells Thus, they become more vulnerable
to damage by further ROS insults induced by exogenous agents
[11]. Under persistent intrinsic oxidative stress, many cancer cells
become well-adapted to such stress and develop an enhanced
endogenous antioxidant capacity [12] which makes the malignant
cells resistant to exogenous chemical [13] or physical exogenous
injuries [14]. The mechanisms of cancer cell redox adaptation
may involve multiple pathways to activate redox-sensitive
transcription factors such as NF-kB or Nrf-2 [15,16] which can,
among others, lead to the increased expression of anti-oxidant
molecules such as SOD, catalase, thioredoxin and the GSH anti-
oxidant system [17]. GSH is the major ROS-scavenging system in
cells and the important redox modulating enzymes including the
peroxidases, peroxiredoxins and thiol reductases rely on the pool
of reduced GSH in the cell as their source of reducing equivalents
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14558[18]. Therefore, strategies to induce a loss of reduced GSH pool
are expected to have a major effect on cell survival and sensitivity
toward irradiation by altering the ability of cells to detoxify ROS
and therefore by triggering cell death. This can be achieved by
targeting its synthesis with buthionine sulfoximine (BSO), an
inhibitor of glutamylcysteine ligase (c-GCL), the rate-limiting
enzyme for GSH synthesis. Previous reports have presented
evidence for the effectiveness of BSO in inhibiting in vitro growth
inhibition of cancer cell lines whether used alone [19] or more
generally in combination with irradiation [20–24] or other drugs
[25–29]. In contrast to this, only a few results of in vivo effects of
BSO [25,30–32] have been reported up to now. Moreover, only
one phase I clinical trial with BSO and melphalan [33,34] has
been undertaken with disappointing results in terms of GSH
depletion. Despite these unfavorable results in vivo, a recent review
[35] has pointed out the high potential of a redox-modulating
strategy to improve cancer treatment.
Epithelial tumors, including HNSCC, contain cellular hetero-
geneity, some of which, termed cancer stem cells (CSC), possess
extensive self-renewal capability and drive tumorigenesis. Up to
now, current treatment for HNSCC may selectively kill the
differentiated cancer cells, producing tumor regression while
sparing the CSC, leading to regrowth and relapse. The recognition
of the potential importance of stem cell patterns in tumor renewal
has now led to the realization that successful therapies at least need
to include CSCs within their range of fatal actions [36,37].
The aim of this work was to design a therapeutic strategy before
irradiation through a transient modification of thiol redox
homeostasis in order to overcome radioresistance of HNSCC.
This was achieved on SQ20B cells as a model of radioresistant
squamous cell carcinoma by the combined use of a GSH depleting
agent, dimethylfumarate and the c-GCL inhibitor BSO before
irradiation. Owing to the crucial roles of cancer stem cells in
HNSCC tumour initiation, disease recurrence and radioresistance,
this pharmacological approach was for the first time tested and
validated either in HNSCC stem or non-stem cells. In addition,
preclinical successful results are presented which highlight the
potential of this redox-modulating strategy in HNSCC treatment.
Materials and Methods
Drugs and reagents
Buthionine sulfoximine (BSO), dimethylfumarate (DMF), MTT,
SP600125 and other reagents were purchased, from Sigma-
Aldrich (Saint-Quentin Fallavier, France). Anti-Bid, anti-JNK
(phosphorylated on Thr183/Thr185), anti-ASK-1 (phosphorylat-
ed on Thr845) polyclonal antibodies were supplied by Cell
Signaling Technology (Danvers, MA), anti-caspase-8 monoclonal
antibody from StressGene (Ann Arbor, MI); anti-ASK-1, anti-
erk1/2 (phosphorylated on Thr202/Tyr204), anti-p38-MAPK
(phosphorylated on Thr180/Tyr182) polyclonal antibodies from
Epitomics Inc (Burlingame, CA), anti-cytochrome c monoclonal
antibody was supplied by BD Biosciences (San Jose, CA), anti-
GAPDH monoclonal antibody from Biodesign International
(Saco, ME), anti-Bax polyclonal antibody and the secondary
antibodies used (horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit IgG) from SantaCruz Biotechnology Inc
(Santa Cruz, CA).
Cell culture and treatment
The HNSCC SQ20B cells was cultured in Dulbecco’s modified
Eagle’s medium (PAA, Pasching, Austria) supplemented with 10%
(v/v) fetal calf serum, 100 unit/ml penicillin, 0.1 g/l streptomycin,
0.04 mg/l hydrocortisone at 37uCi n5 %C O 2.
Irradiation of cells
Cells were irradiated with X-rays on a Clinac CD irradiator
(Varian Medical System, Palo Alto, CA), at a dose of 10 Gy
delivered at a dose rate of 3 Gy/min in the Radiotherapy
Department of Lyon-Sud Hospital Center.
MTT assay
About 8.000 cells/well were grown in 96-well microtiter plates,
incubated overnight in 100 ml of culture medium and then treated
with different concentrations (0 to 500 mM) of DMF and/or BSO
for 24 h. 10 ml of MTT labelling reagent (0.5 mg/ml) was added
and the cells were incubated for another 4 h at 37uC. The
supernatant was removed and 100 ml of 0.04 mol/l hydrochloric
acid in isopropanol was added. The absorbance was measured at
595 nm.
HPLC analysis
Total glutathione was quantified by HPLC analysis. Briefly,
proteins were precipitated from the cellular homogenate with
sulfosalicylic acid and centrifuged at 13.0006g. The supernatant
was then derivatized with o-phthalaldehyde. Chromatographic
separation was achieved on a 5 mm Spherisorb C18-column, with
a mobile phase of methanol – 0.15 M acetate buffer pH 7
(7.5:92.5). Fluorescence of the glutathione-o-phthalaldehyde de-
rivatives was detected at 420 nm with excitation of 340 nm [4].
Flow cytometry analysis
For cell cycle analysis, cells were pelleted by centrifugation at
3006g, washed once in PBS at 4uC and fixed in ice-cold 70%
ethanol before storage at 220uC for at least 24 h until use. After
washing, cells were resuspended in 1 ml PBS containing 1 mg/ml
RNase-A and 5 mg/ml of propidium iodide and incubated for
20 min in the dark at room temperature before flow-cytometry
analysis in red fluorescence (FL 2).
To measure Dym, cells were incubated for 20 min with 5 mg/
ml 5,596,69-tetra-chloro-1,19,3,39-tetraethylbenzyl-imidazolcarbo-
cyanine iodide (JC-1) (Molecular Probes, Leiden, The Nether-
lands) in the dark before flow cytometry analysis in green
fluorescence (FL 1).
To measure total caspase activation, cells were incubated with
5 mM CaspACE-FITC-VAD-FMK in situ marker (Promega,
Madison, WI) for 20 min in the dark. Cells were analyzed by
flow cytometry in green fluorescence (FL 1).
Finally, to measure the intracellular ROS level, cells were
incubated for 10 min with hydro-ethidium (final concentration
4 mM) in the dark at 37uC. The reaction was stopped at 4uC
before analysis by flow cytometry in red fluorescence (FL 2).
DAPI Staining
Cells were fixed with 4% paraformalde ´hyde for 30 min and
stained with the fluorescent nuclear dye, 49,6-Diamidino-2-
phenylindole dihydrochloride (DAPI, 5 mg/ml) for 30 min.
Apoptotic cells were identified with fluorescence microscopy by
the presence of apoptotic bodies.
Mitochondria isolation
Mitochondria were isolated with the Mitochondria Isolation Kit
for Cultured Cells (Pierce, Rockford, IL, USA) according to the
manufacturer’s instructions. Briefly, 8610
6 cells were pelleted by
centrifugation at 3006g and included in lysis buffer. After a
centrifugation at 12.0006g for 10 min at 4uC, the supernatant
containing the cytosolic fraction and the pellet containing the
GSH and Radiosensitization
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Western immunoblotting analysis.
Western immunoblotting
Cells were lysed on ice for 1 h in a buffer containing 150 mM
NaCl, 50 mM Tris (pH 8), 1% Triton X-100 and protease
inhibitors (protease inhibitors cocktail tablets, Roche, France).
Then, lysates were centrifuged for 20 min at 15.0006g. The
protein content was determined with the BCA protein assay.
30 mg of total proteins were separated by SDS-PAGE on 14%
gels and transferred onto nitrocellulose membrane. The mem-
branes were blocked with TBS-0.1% Tween 20 (TBST) – 5% non-
fat dried milk for 1 h, and probed overnight at 4uC with primary
antibody (1:1.000) in TBST – 5% BSA. After washes with TBST,
the membrane was probed with HRP-conjugated secondary
antibodies diluted at 1:10.000 in a blocking buffer. After washes,
membranes were incubated with enhanced chemiluminescence
reagent (Pierce, Rockford, IL, USA), and visualized by Intelligent
Dark-Box LAS-3000 (Fujifilm, Tokyo, Japan).
For ASK-1 immunoblot, only 25 mg proteins were separated on
10% reducing gels. For analysis of caspase-8 was the membranes
were blocked with PBS-0.05% Tween 20–3% non-fat dried milk.
Incubation with primary (1:2.000) and secondary (1:7.500)
antibodies were performed in the same mixture. Finally, for Bax
immune-blot analysis, the primary antibody was diluted at 1:500
and the secondary at 1:2000 in TBS-0.05% Tween 20–5% non-fat
dried milk.
SiRNA transfection in vitro
The ASK-1-validated siRNA was purchased from Qiagen
(Hs_MAP3K5_6 siRNA, Qiagen, Courtaboeuf, France), SQ20B
cells were plated in a 6-well plate (5610
4 cells/well) 24 h before
transfection. Transfection was performed using HiPerfect trans-
fection reagent (Qiagen) according to the manufacturer’s instruc-
tions, with final siRNA concentration at 150 nM. 48 h after
transfection, total cellular ASK-1 was measured by western
immunoblotting.
Cancer stem cells (CSC) isolation
In a first step, SQ20B cells were grown in DMEM supple-
mented with 25% (v/v) F-12, 100 units/ml penicillin, 0.1 g/l
streptomycin, 0.04 mg/l hydrocortisone and 20 ng/ml EGF and
5 mg/ml insulin in order check their ability to form tumouri-
spheres. Then, CSCs were isolated by two successive cell sortings
on a FACS VANTAGE SE DIVA (BD Biosciences, San Jose, CA)
as described [38]. Briefly, SQ20B CSCs were isolated on their
Hoechst dye-excluding property and the expression of the cell
surface marker CD44. The Hoechst dye-excluding cells were
sorted out from 30610
6 SQ20B cells as a side-population (SP)
which was further cultured in DMEM at 37uCi n5 %C O 2. This
culture medium was supplemented with 5% (v/v) fetal calf serum,
25% (v/v) F-12, 100 units/ml penicillin, 0.1 g/l streptomycin,
0.04 mg/l hydrocortisone and 20 ng/ml EGF. After 10 days of
culture, a second cell sorting was performed on a 30610
6 SP cells
after cell labelling with an antibody to CD44 coupled to FITC
(FITC Mouse Anti-human CD44, BD biosciences). The CD44
+
cells were grown in the same environment as SP cells. The CD44
2
cells were grown in SQ20B culture medium. After 10 days, cells
were trypsinized and used for different experiments.
In vivo treatments
All animal procedures were performed according to local
guidelines on animal care. All the details of this study were
approved by the CECCAPP, an ethics committee. A suspension of
2610
6 SQ20B cells in 150 ml of PBS was subcutaneously
inoculated in the right flank region of 5-week-old female athymic
nude mice (Harlan France, Gannat, France) under ketamine/
rompum anesthesia. When tumours reached 0.3–0.4 cm
3 in
volume, mice were randomly selected for treatment. 32 mg/kg
of DMF and 4 mg/kg of BSO were injected in the tumour 4 hours
before irradiation (4 Gy/day) for 5 days. Local tumour irradiation
was performed under anesthesia at a dose rate of 3 Gy/min.
Experiments consisted of 4 groups of 9 mice: PBS, DMF/BSO,
564 Gy and DMF/BSO + 564 Gy. Clinical observations were
carried out daily alongside weekly measurements of body weight
and tumour volume, which was calculated according to the
formula: 0.5236(LxW
2) where L and W are, respectively, the
length and width diameters.
Total intra-tumoral glutathione was quantified from tumour
extracts by HPLC, as described above.
TUNEL assay
Terminal nucleotidyl transferase-mediated nick end labelling
staining was carried out on formalin-fixed, paraffin-embedded
tissue sections (5 mm) with the DeadEnd Fluorimetric TUNEL
System (Promega, Madison, WI) according to the manufacturer’s
instructions. Slides were examined using a Zeiss Microscope at a
wavelength of 520 nm.
Statistical analysis
Student’s t-test calculation was performed using Microsoft Excel
2003. Student’s t-test was used to determine the significance of the
differences (a p-value of ,0.05 was considered statistically
significant).
Results
Effects of DMF and BSO on cell viability and endogenous
GSH depletion
In a first set of experiments, we aimed at defining the in vitro
toxicity of the glutathione-depleting agent DMF and the
glutathione biosynthesis inhibitor BSO used either alone or in
combination. As shown in Figure 1A, 90% and 83% of cells were
still viable 24 hours after a treatment with 100 mM BSO or
100 mM DMF, respectively. Cell viability was considerably
reduced at higher concentrations. A combination of 100 mMo f
each drug for 24 h resulted in a cell viability of around 75%. In
order to avoid the cytotoxic effect of drugs, we further examined
the effect of a transient pre-treatment of SQ20B cells 4 h before
irradiation with 100 mM DMF, 100 mM BSO or in combination
(Fig. 1B) which were immediately removed after irradiation by
washing with fresh medium. As depicted in Figure 1B, treatment
with DMF alone resulted in a rapid and transient decrease in
intracellular GSH to about 60% of the initial concentration, 4 h
after the treatment, and was followed by a strong and rapid
increase in GSH (up to 180% compared to the control) which
peaked 8 h after DMF addition. With BSO alone, cells rapidly lost
40% of their endogenous GSH in the first 3 h, followed by a
sustained decrease to 10% of the initial concentration at 24 h.
When used in combination, DMF and BSO resulted in total
cellular GSH depletion at 4 h with complete restoration of the
endogenous GSH level at 60 h after washing SQ20B cells with
fresh culture medium (Fig. 1C). A 4-hour exposure to DMF and
BSO before irradiation was therefore considered as optimal to
efficiently deplete SQ20B GSH stores before irradiation without
significantly affecting cell viability or subsequent survival in
culture.
GSH and Radiosensitization
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endogenous glutathione modulation before irradiation
Figure 2 shows that GSH-depleted SQ20B cells can undergo
apoptosis after a 10 Gy irradiation as evidenced by a significant
increase in total caspase activity from 48 h after irradiation up to
60% of positive cells 96 h after irradiation (Fig. 2A). To the same
extent, up to 60% of pre-treated SQ20B cells were found as
hypodiploid (sub-G1) apopototic cells 96 h after irradiation
(Fig. 2B). These data were confirmed by DAPI staining which
revealed the presence of apoptotic bodies (Fig. 2C) as a result of
chromatin condensation and nuclear fragmentation. The involve-
ment of the intrinsic apoptotic pathway was further evidenced by
the loss of mitochondrial Dym and the production of ROS.
Irradiation of GSH-depleted SQ20B cells induced a strong
decrease in Dym (Fig. 2D) with a parallel significant increase in
ROS production (Fig. 2E) from 48 h after irradiation.
Effects of transient GSH depletion combined with
irradiation on the activation of SAPK pathways and Bax
translocation to mitochondria
Figure 3A shows a slight and transient increase of the
phosphorylation state of p42- and p44-MAPK (Erk) up to
30 min which then declined 60 min after irradiation of GSH-
depleted SQ20B cells. In contrast, the p38-MAPK phosphoryla-
tion state did not change during the time course studied. As
opposed to p38 and Erk-MAPK, a transient increase of the
phosphorylation state of JNK/SAPK was observed from 60 min
up to 120 min and then declined after irradiation of GSH-
depleted SQ20B cells (Fig. 3B) thus strongly suggesting that JNK/
SAPK plays a role in the downstream effects of GSH depletion in
irradiated SQ20B cells. This result was confirmed by using
SP600125, a specific JNK/SAPK inhibitor (Fig. 3C) which
resulted in a more than 80% inhibition of apoptosis of irradiated
GSH-depleted cells (Fig. 3D). Upstream of JNK, apoptosis signal-
regulating kinase (ASK-1) has been reported [39] as a key
MAPKKK connecting oxidative stress and ROS to JNK.
Figure 4A shows a significant increase in the phosphorylation of
ASK-1, 30 min after irradiation of GSH-depleted SQ20B cells
followed by a rapid decrease for longer periods. This result was
confirmed after downregulating the expression of ASK-1 with a
specific short interfering RNA. As depicted in Figure 4B, the
successful silencing of ASK-1 resulted in a strong decrease in
JNK/SAPK activation in irradiated GSH-depleted SQ20B cells.
As a consequence, the number of apoptotic cells was strongly
inhibited (Fig. 4C) as evidenced by the measurement of the total
caspase activity. The involvement of the intrinsic apoptotic
pathway after irradiation of GSH-depleted SQ20B cells was
further confirmed by the translocation of the pro-apoptotic Bax
protein from the cytosol to mitochondria (Fig. 5A) whereas no
cleavage of either pro-caspase-8 and Bid occurred under the same
experimental conditions (Fig5B). Additionally, Bax translocation to
mitochondria was correlated with the release of cytochrome c in
the cytosol, as depicted in Figure 5C.
Modulation of redox status in HNSCC stem cells as a
useful tool to overcome radioresistance in vitro?
Tumorigenic HNSCC stem cells were isolated from the SQ20B
cell line [38] according firstly to their ability for three dimensional
growth (tumourisphere formation) and secondly to their Hoechst
dye excluding property and the presence of the surface stem cell
marker CD44. The fraction of high expressing CD44
+ subpop-
ulation was found to be as low as 0.1% in the SQ20B cell line. The
quantification of the endogenous reduced glutathione content in
CD44
+ and CD44
2 cells showed that they exhibited approxi-
mately the same amount of GSH i.e 76.361.6 nmol/mg protein
and 73.460.9 nmol/mg protein in CD44
+ and CD44
2 cells,
respectively. Treatment of CD44
+ and CD44
2 cells with the
association DMF + BSO resulted in a GSH depletion at 4 h to
11% and 17% of basal level in control CD44
+ and CD44
2 cells,
respectively (data not shown). As depicted in Figure 6A and 6B,
GSH-depleted CD44
+ and CD44
2 cells were able to undergo
Figure 1. In vitro cytotoxicity and efficiency of the glutathione
depleting strategy using the pharmacological association of
DMF + BSO. SQ20B cells were plated and treated by DMF and/or BSO.
Panel A shows the survival of SQ20B cells, determined by the MTT assay,
after 24 h of continuous treatment with increasing concentrations of
both drugs. Panel B shows the endogenous glutathione level,
determined by HPLC, after continuous treatment with DMF (100 mM)
and/or BSO (100 mM). In a second set of experiments, panel C shows the
endogenous glutathione level with and without 10 Gy irradiation and
after treatment with DMF (100 mM) and BSO (100 mM) for 4 h. The drugs
were then removed by washing with fresh medium. Results are
expressed as mean 6 S.D. for three different experiments in triplicate.
doi:10.1371/journal.pone.0014558.g001
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G1 phase increased with time from 48 h after irradiation and show
a similar pattern in both subpopulations (up to 40% of sub-G1
cells, 120 h after irradiation). As reported for the whole SQ20B
cells, an increase in the level of ROS (Fig. 6C and 6D) and a
decrease in the Dym (Fig. 6E and 6F) occurred in both GSH-
depleted subpopulations. All these results demonstrate that our
targeted treatment can overcome radioresistance in HNSCC stem
cells.
Modulation of HNSCC redox status as a useful tool to
prevent in vivo tumor regrowth and relapse?
Preliminary experiments were conducted in order to define the
optimal conditions in vivo for intra-tumoral GSH depletion. As
depicted in Figure 7A, a single DMF (32 mg/kg) and BSO (4 mg/
kg) intra-tumoural injection resulted in a 60% decrease in GSH
within the tumour 4 h after treatment followed by a total recovery
of GSH 24 h after the treatment. Although a progressive increase
in tumour volume (Figure 7B) was observed in the control groups,
a 4 Gy irradiation during five consecutive days stabilized the
development of the tumour up to 5 weeks which then started to
develop again. Although a single injection of DMF/BSO had no
significant effect on tumour growth compared to the control
group, the combination of our GSH-depleting strategy 4 hours
before irradiation (one injection before each session of irradiation,
4 Gy for 5 days) drastically enhanced the sensitivity of the
xenografted SQ20B tumours to irradiation. At the end of the
treatment (week 9), the mean tumour volume had decreased by
95% compared to the control group and by 75% compared to the
irradiated control group. This was obtained in the absence of
apparent toxicity as evidenced by the recording of mice body
weight (Figure 7C). Finally, an increase in the overall survival of
mice, as represented by the Kaplan-Meyer curves (Fig. 7D)
confirmed the efficiency of the treatment prior to irradiation.
TUNEL staining of tumour sections confirmed the results
obtained in vitro: the combined treatment of DMF/BSO and
radiation resulted in large areas of apoptosis (Fig. 7E).
Discussion
The survival rate of patients with HNSCC has not improved
significantly despite multimodal therapy including surgery,
radiation therapy and chemotherapy. As up-regulation of
antioxidant capacity is a crucial point in the development of radio
and/or chemoresistance in numerous cancer cells [40], the aim of
Figure 2. Depletion of endogenous glutathione content before c-ray exposure triggers radiation-induced intrinsic apoptosis in
SQ20B cell line. SQ20B cells were treated with 100 mM DMF and 100 mM BSO for 4 h before irradiation. The drugs were then removed by washing
with fresh medium. Total caspase activity and the percentage of cells in the sub-G1 phase were determined by flow cytometry, respectively after
VAD-FMK-FITC (A) and propidium iodide (B) staining. Panel C shows the nuclear morphology of cells by DAPI staining 72 h post irradiation. Panels D
and E show the mitochondrial alteration after JC-1 staining through the measurement by flow cytometry of the transmembrane potential (A) and
after hydro-ethidine staining to measure the reactive oxygen species generated by respiratory chain (B). Results are expressed as mean 6 S.D. for
three different experiments in triplicate. The statistical significance is expressed as **, p,0.01 and ***, p,0.001 versus 10 Gy only.
doi:10.1371/journal.pone.0014558.g002
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transient depletion, just before irradiation, of intracellular stores of
GSH in the radioresistant HNSCC cell line in order to maximize
the oxidative stress generated after exposure to c-rays.
We first experimented the use of dimethylfumarate (DMF) alone
to achieve a rapid depletion of the intracellular stores of GSH in
SQ20B cells. DMF has been widely used in the treatment of
psoriasis [41] and used in a few studies to enhance cytotoxicity of
antitumour agents [42] or induce cell cycle arrest in colon
carcinoma cells [43]. Apparently, the depleting effect of DMF
results from the formation of a conjugate between DMF and GSH
that is exported and/or metabolized by the cell [44]. Our results
show that DMF alone triggers a rapid depletion of GSH to only
60% of the initial content followed by an overshoot prior to a
recovery of the initial GSH concentration 48 h after the beginning
of the treatment. This confirms the assumption mentioned above
of a redox adaptation of SQ20B cells to oxidative stress through
the stimulation of endogenous GSH biosynthesis, once a threshold
of low endogenous concentration was reached. In that sense, RT-
qPCR analysis showed significant over-expression in SQ20B cells
of critical GSH metabolism enzymes such as c-GCL, glutathione
synthase (GS) and gluthathione reductase (GR) when compared to
the radiosensitive HNSCC SCC61 cell line (data not shown). We
therefore included BSO, an inhibitor of GSH synthesis, before
irradiation in order to amplify GSH depletion just before
irradiation and to avoid its rapid re-synthesis in SQ20B cells.
This experimental approach allowed us to trigger apoptosis in the
radioresistant SQ20B cell line (see Figure 2). Previous studies have
already tested this pharmacological association in irradiated
normal [45] and cancer cells [46,47] with either toxic effects or
only a slight radiosensitizing effect in vitro. As a consequence of
irradiation, the major oxidative stress obtained under our
experimental conditions rapidly activated ASK-1, a ROS-
dependent activated kinase [48,49] which is known to further
activate JNK or p38 pathways [50,51]. Previous work in our
laboratory has demonstrated that radioresistance of SQ20B cells is
partially correlated to a defect in raft membrane clustering [14].
Overcoming the endogenous antioxidant defences through either
exogenous H2O2 or BSO treatment was shown to restore the
activation of an A-Smase followed by its translocation to the outer
Figure 3. Involvement of the MAPK pathway in the triggering of apoptosis after transient intracellular GSH depletion before
irradiation. SQ20B cells were treated with 100 mM DMF and 100 mM BSO for 4 h whereas 10 mM SP600125, a specific JNK inhibitor, was added 1 h
before irradiation in the cell culture medium before irradiation. The drugs were then removed by washing with fresh medium. After different points in
time after irradiation, cells were harvested and the extracted proteins submitted to Western blot analysis. Panel A: Western blot analysis of
phosphorylated Erk, p38 MAPK, and GAPDH. Panel B: Western blot analysis of inhibition of JNK phosphorylation by SP600125. Panel C: Western blot
analysis of phosphorylated JNK and GAPDH. Panel D shows the consequence of JNK inhibition in terms of apoptosis estimated by flow cytometry
through the total caspase activity (left) and the % of cells in sub-G1 phase (right) measurement 72 h after irradiation. Results are expressed as mean
6 S.D. for three different experiments. The statistical significance is expressed as ***, p,0.001 versus 10 Gy only.
doi:10.1371/journal.pone.0014558.g003
GSH and Radiosensitization
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coalescence into signalling platforms and ceramide release. As
ceramide was recently reported to possibly activate ASK-1 [52],
the early ceramide release within rafts mentioned above could also
act upstream of ASK-1 activation in parallel to that caused by
ROS. Once the JNK pathway was activated, the intrinsic
Figure 4. Activation of Ask1 upstream of the MAPK pathway in irradiated GSH-depleted SQ20B cells. SQ20B cells were treated with
100 mM DMF and 100 mM BSO for 4 h before irradiation. The drugs were then removed by washing with fresh medium. At different times post
irradiation, cells were harvested and the extracted proteins submitted to Western blot analysis. Panel A: levels of phosphorylated Ask1 Panel B: levels
of ASK-1 after specific siRNA transfection and downstream phosphorylation of JNK. Panel C: control of apoptosis through the measurement of total
caspase activity 72 h after transfection of irradiated GSH-depleted cells with Ask1 SiRNA. Results are expressed as mean 6 S.D. for three different
experiments. The statistical significance is expressed as ***,p ,0.001 versus 10 Gy only.
doi:10.1371/journal.pone.0014558.g004
Figure 5. Translocation of the pro-apoptotic protein Bax to mitochondria and release of cytochrome c in the cytosol of irradiated
GSH-depleted SQ20B cells. SQ20B cells were treated with 100 mM DMF and 100 mM BSO for 4 h before irradiation. The drugs were then removed
by washing with fresh medium. At different time post irradiation, mitochondria were isolated with standard fractionation procedure. The
translocation of Bax to mitochondria (Panel A) and the release of cytochrome c in cytosol (Panel C) were measured by Western immunoblotting assay.
In parallel, the activation of pro-caspase 8 and the cleavage of Bid were estimated by Western blot analysis (Panel B).
doi:10.1371/journal.pone.0014558.g005
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pro-apoptotic protein Bax to mitochondria which resulted in the
alteration of this organelle as recently reviewed by Dhanasekaran
and Reddy [53]. The great time interval between GSH depletion
together with irradiation and triggering of apoptosis reflects the
time needed by the cell for DNA double-strand breaks (DSBs)
repair after irradiation, the residual DSBs being crucial down-
stream apoptosis-triggering lesions [54]. As radioresistant cells
including HNSCC are very effective in repairing DNA DSBs [55],
combining DMF/BSO treatment with radiation was the only way
in this study to trigger cell death. As this combination has proven
to be also effective with CD44+ cells, this is expected to be a
promising strategy to overcome local recurrence in HNSCC.
As epithelial tumors, including HNSCC were recently demon-
strated to contain cellular heterogeneity, some of which represent
highly tumorigenic subpopulations called ‘‘cancer stem-like cells’’
[38,56,57], more effective therapies targeted against this critical
population that can overcome radioresistance and improve patient
outcome are needed. The second part of our work has therefore
been devoted to the validation of our transient GSH-depleting
strategy on HNSCC cancer stem-like cells before irradiation.
Preliminary determination of the endogenous GSH content shows
no significant differences in both CD44
+ and CD44
2 subpopu-
lations. Correlatively, RT-qPCR analysis of critical GSH metab-
olism gene expression showed a significant over-expression of GS
and GR in CD44
+-enriched cells compared to CD44
2 (data not
Figure 6. Increase of intrinsic apoptosis in irradiated HNSCC cancer stem cells. After cell sorting, two sub-populations were obtained from
the SQ20B carcinoma cell line: CD44
+ cancer stems cells (A, C, E) and a CD44
2 side population (B, D, F) which were grown in the SQ20B culture
medium for 10 days. Both cell populations were treated with 100 mM DMF and 100 mM BSO for 4 h before irradiation and drugs were then removed
by washing with fresh medium. At different times after irradiation, the percentage of apoptotic cells was quantified by flow cytometry analysis. Panels
A and B: quantification of apoptotic cells in the sub-G1 phase after propidium iodide staining of CD44
+ (A) and CD44
2 (B) sub-populations. Panels C
and D: quantification of ROS after hydro-ethidium staining of CD44
+ (C) and CD44
2 (D) sub-populations. Panels E and F: Quantification of the
mitochondrial transmembrane potential decrease after JC-1 staining of CD44
+ (E) and CD44
2 (F) subpopulations. Results are expressed as mean 6
S.D. for three different experiments. The statistical significance is expressed as *,p ,0.05, **,p ,0.01 and ***,p ,0.001 versus 10 Gy only.
doi:10.1371/journal.pone.0014558.g006
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GS in human breast CSCs [58]. Although the over-expression of
such genes in CSC is believed to be involved in the rapid GSH re-
synthesis after major oxidative stress or pharmacological depletion
(see our results with DMF alone in Figure 1B for example), future
work is needed to explain the apparent discrepancy between the
endogenous GSH content and the intrinsic radiosensitivity of our
subpopulations as previously reported for other cell lines [59,60].
In all events, exposure of CD44
+ cancer stem-like cells to
irradiation after a 4-hour DMF + BSO treatment resulted in a
triggering of the intrinsic apoptotic pathway as efficiently as in the
whole SQ20B cell population.
We next evaluated in vivo the potential radiosensitizing effect of
DMF + BSO on SQ20B tumours. We firstly verified the
effectiveness of a single intra-tumoural injection of both drugs in
depleting GSH which decreased to 40% of the initial value in the
tumour (with or without irradiation) and returned to control values
24 h after the injection of drugs. After delivering a dose of 4 Gy
daily for 5 days (20 Gy total), our data show a real efficiency of our
pre-treatment illustrated by a decrease of 95% in the mean tumour
volume in the absence of apparent toxicity in mice. Moreover, this
work clearly shows that the induction of apoptosis is a critical
determining factor in tumour radiosensitivity. Finally, 80% of mice
were shown to survive up to 9 weeks after irradiation as depicted in
Figure 7. Combined treatment of DMF + BSO with irradiation enhances the survival of mice and inhibits tumor growth without
apparent cytoxicity. Panel A shows the efficiency of a single intratumoural injection of 32 mg/kg DMF and 8 mg/kg BSO on the depletion of GSH
within the tumour. Panel B shows the relative development of tumour size after combined DMF + BSO treatment each day whether or not associated
with an irradiation dose of 20 Gy (4 Gy65 days). The statistical significance is expressed as *, p,0.05, **, p,0.01 between treated and irradiated
tumours versus irradiated tumours. Panel C shows the body weight monitoring of mice after the combined DMF + BSO treatment whether or not
associated with an irradiation dose of 20 Gy (4 Gy65 days). Panel D shows the Kaplan-Meyer survival curves representing the percentage of mice
alive at the indicated points in time for each group of the experiment. Panel E shows the detection of apoptosis by TUNEL staining on paraffin-
embedded tumor sections.
doi:10.1371/journal.pone.0014558.g007
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strongly underline the therapeutic potential of this adjuvant
therapy to irradiation in head and neck carcinoma.
As indicated in a very recent review [35], redox adaptation,
through an increased intracellular antioxidant capacity, is an
important concept that explains to a large degree the mechanisms
by which cancer cells, particularly CSCs, become resistant to
radiotherapy and/or anticancer agents.
HNSCC is a complex and aggressive cancer characterized by
the emergence of therapy-resistant local and regional recurrences.
Apart from the development of new molecular targeted [61,62] or
gene therapies [63], our results, in accordance with Trachootham
et al [35] highlight the potential of using redox-modulating stategy
in combination with radiotherapy to specifically eliminate highly
tumourigenic CSCs. Moreover, the triggering of apoptosis instead
of mitotic cell death under these experimental conditions is a
fundamental result to prevent further potential local recurrence of
HNSCC.
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